Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, and Chronic Lymphocytic Leukemia Research.
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia
Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.
Genetic characterization of AML defined by differentiation shows a high frequency of DDX41 mutations.
The clinical relevance of sole loss of chromosome Y in myeloid neoplasms.
The FGFR1 N546K mutation confers resistance to pemigatinib in MLN-ZMYM2::FGFR1.
Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes.
Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.
Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease
STAT5B leukemic mutations, altering SH2 tyrosine 665, have opposing impacts on immune gene programs
Diagnosis of acute lymphoblastic leukaemia: an overview of the current genomic classification, diagnostic approaches, and future directions.
Telomere content and genomics of myeloid neoplasia by whole-genome sequencing
Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations.
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker
Myeloid neoplasms with MYC-positive double minutes: towards recognition as a distinct entity.
Inter-modality variance of blast quantification in patients with myelodysplastic neoplasms (MDS) and its impact on risk stratification and overall survival
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting.
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase.
Genomic landscape of CCUS compared to MDS and its implications on risk prediction.
Parallel genomic analysis from paired bone marrow and peripheral blood samples of 200 cytopenic patients.
Abstract 4145859: Clonal Hematopoiesis of Indeterminate Potential Increases Mortality Risk in Coronary Artery Disease
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes